Author:
Munir Saira,Saleem Sana,Idrees Muhammad,Tariq Aaliyah,Butt Sadia,Rauff Bisma,Hussain Abrar,Badar Sadaf,Naudhani Mahrukh,Fatima Zareen,Ali Muhmmad,Ali Liaqat,Akram Madiha,Aftab Mahwish,Khubaib Bushra,Awan Zunaira
Abstract
Abstract
Hepatitis C virus (HCV) is a member of Flaviviridae family and one of the major causes of liver disease. There are about 175 million HCV infected patients worldwide that constitute 3% of world's population. The main route of HCV transmission is parental however 90% intravenous drug users are at highest risk. Standard interferon and ribavirin remained a gold standard of chronic HCV treatment having 38-43% sustained virological response rates. Currently the standard therapy for HCV is pegylated interferon (PEG-INF) with ribavirin. This therapy achieves 50% sustained virological response (SVR) for genotype 1 and 80% for genotype 2 & 3. As pegylated interferon is expensive, standard interferon is still the main therapy for HCV treatment in under developed countries. On the other hand, studies showed that pegylated IFN and RBV therapy has severe side effects like hematological complications. Herbal medicines (laccase, proanthocyandin, Rhodiola kirilowii) are also being in use as a natural and alternative way for treatment of HCV but there is not a single significant report documented yet. Best SVR indicators are genotype 3 and 2, < 0.2 million IU/mL pretreatment viral load, rapid virological response (RVR) rate and age <40 years. New therapeutic approaches are under study like interferon related systems, modified forms of ribavirin, internal ribosome entry site (HCV IRES) inhibitors, NS3 and NS5a inhibitors, novel immunomodulators and specifically targeted anti-viral therapy for hepatitis C compounds. More remedial therapies include caspase inhibitors, anti-fibrotic agents, antibody treatment and vaccines.
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Virology
Reference58 articles.
1. Asselah T, Estrabaud E, Bieche I, Lapalus M, De Muynck S, Vidaud M, Saadoun D, Soumelis V, Marcellin P: Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int 2010. ISSN 1478-3223
2. Alter MJ: Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007,13(17):2436-41.
3. Butt AA: Hepatitis C virus infection: the new global epidemic. Expert Rev Anti Infect Ther 2005, 3: 241-9. 10.1586/14787210.3.2.241
4. Soriano V, Peters MarionG, Zeuzem S: New Therapies for Hepatitis C Virus Infection. Clinical Infectious Diseases 2009, 48: 313-20. 10.1086/595848
5. Koziel M, Peters M: Viral hepatitis in HIV infection. N Engl J Med 2007, 356: 1445-54. 10.1056/NEJMra065142
Cited by
78 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献